FILE - This April 21, 2010 file photo, shows the logo of Amgen Inc. offices, in Fremont, Calif. Amgen Inc. reports quarterly earnings Thursday, Jan. 26, 2012, after the market close. (AP Photo/Paul Sakuma, file)
FILE - This April 21, 2010 file photo, shows the logo of Amgen Inc. offices, in Fremont, Calif. Amgen Inc. reports quarterly earnings Thursday, Jan. 26, 2012, after the market close. (AP Photo/Paul Sakuma, file)
THOUSAND OAKS, California (AP) ? Amgen Inc. said Thursday that its fourth-quarter profit fell 8.5 percent as its expenses for taxes and producing and selling drugs rose faster than its revenue.
The world's largest biotech company said its net income was $934 million, or $1.08 per share, down from $1.02 billion, also $1.08 per share, a year earlier.
Excluding one-time items, it said it earned $1.04 billion, or $1.21 per share, down 6 percent from $1.1 billion, or $1.17 per share.
Revenue was $3.97 billion, up 3 percent from $3.84 billion in 2010's fourth quarter.
Analysts on average expected earnings per share of $1.22 and sales of $3.92 billion, according to FactSet.
"We exited 2011 with good momentum, and the outlook for 2012 is even stronger," CEO Kevin Sharer, who is stepping down in May, said in a prepared statement.
Amgen said this expects to earn $5.90 to $6.15 per share for 2012, excluding one-time items, and take in revenue of about $16.3 billion. Analysts were expecting $5.97 per share in adjusted earnings and $16.06 billion in revenue for the year.
Earlier Thursday, the maker of biologic drugs for cancer and blood disorders said it plans to buy cancer therapy developer Micromet Inc. for $1.16 billion in cash to boost its oncology pipeline. Founded in Germany and based in Rockville, Maryland, Micromet is developing an experimental antibody-based drug, blinatumomab. It's currently in mid-stage testing to treat leukemia and in clinical development for the treatment of non-Hodgkin lymphoma.
The purchase is Amgen's largest since it bought BioVex Group last year in a deal worth up to $1 billion, including milestone payments.
For the full year, Amgen reported net income of $3.68 billion, or $4.04 per share, down 20 percent from $4.63 billion, or $4.79 per share in 2010. Adjusted income was $4.86 billion, or $5.33 per share, down 3 percent from $5.02 billion, or $5.21 per share. Revenue was up 3 percent to $15.58 billion, from $15.05 billion.
Analysts were expecting adjusted income of $5.33 per share on average and revenue of $15.51 billion.
Amgen shares were unchanged following the after-hours report. They ended regular trading Thursday down $1.13, or 1.6 percent, at $68.08.
Associated Pressrussell pearce russell pearce emergency alert system 21 jump street 19 kids and counting 2011 election results 11/11/11
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.